Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 3,900 trials

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Acute Leukemia: Bleximenib Study

We are testing a new drug called Bleximenib for people with acute leukemia to find the best dose and check its safety. We also want to see if it helps improve treatment outcomes.

Acute Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematology

Acute Myeloid Leukemia: Bleximenib Treatment Study

We are testing a new drug, bleximenib, combined with current therapies for patients with acute myeloid leukemia who have certain genetic changes. The goal is to find the best dose and ensure it is safe for use.

Acute Myeloid Leukemia>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Early Rectal Cancer: FARE Trial with [68Ga]Ga-FAPI-46 PET/CT

We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.

Rectal Cancer≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOtolaryngology

Severe Depression: Ketamine vs. Placebo

We are studying whether adding ketamine to venlafaxine helps hospitalized patients with severe depression feel better faster than a placebo. We’re also looking at its effects on hospital stay and side effects.

Major Depressive Disorder1-2 yearsConfirmation phase (III)Investigational MedicinesPsychiatry

Liver Transplant: Single vs. Twice Daily Immunosuppressive Doses

We are studying whether a single daily dose of immunosuppressive medication is as effective as a twice-daily dose for liver transplant recipients. This trial also compares two different formulations of tacrolimus to see which works better.

Transplantation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHepatologyInternal Medicine

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Solid Tumors: PF-08046054/SGN-PDL1V Study

We are investigating a new treatment for patients with advanced solid tumors. The goal is to see if it can improve outcomes compared to current therapies.

Non-small Cell Lung CancerOesophageal Squamous Cell CarcinomaGastric Cancer>2 yearsSafety phase (I)Oncology

Bipolar Depression: New Treatment Approach

We are investigating whether a six-week intensified medication plan helps people with bipolar depression who didn't respond to their first treatment. We’ll compare this new approach to standard care to see which is more effective.

Bipolar Depression≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Alzheimer's Disease in Down Syndrome: Sleep and Temperature Study

We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.

Down SyndromeAlzheimer's Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurologyPsychiatry

Heart Health: Ticagrelor with Aspirin After CABG

We are studying whether adding ticagrelor to aspirin helps reduce heart-related events in patients after coronary artery bypass surgery. This trial also looks at the risk of bleeding and graft failure.

Coronary Artery Disease>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lennox-Gastaut Syndrome: Carisbamate Treatment Study

We are investigating whether carisbamate can help reduce drop seizures in children and adults with Lennox-Gastaut Syndrome. This study will also look at the safety and tolerability of the medication.

Lennox-Gastaut Syndrome3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Crohn's Disease: Dual Biological Therapy Study

We are evaluating whether a combination of medications can help patients with Crohn's disease who haven't responded to previous treatments. The study compares single therapies to combination therapies to find the most effective approach.

Crohn's DiseaseEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Ulcerative Colitis: Dual Therapy Study

We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.

Ulcerative Colitis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dapagliflozin for Heart Protection in Breast Cancer Patients

We are studying whether dapagliflozin can help prevent heart problems in breast cancer patients receiving chemotherapy. This trial compares its effects to a placebo over 12 months.

Secondary CardiomyopathyInvasive Breast Cancer3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyOncology